We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nanotechnology Could Combat Antibiotic-Resistant Infections in Open Bone Fractures

By HospiMedica International staff writers
Posted on 14 Nov 2024

Every year, over 150,000 people in the United States experience open bone fractures. More...

Approximately 10% of these individuals develop infections, which can result in reduced limb function, additional surgeries, delayed healing, or even death. The risk of infection is further complicated by antibiotic resistance, where bacteria evolve the ability to resist the medication meant to eliminate them, allowing the infection to persist and worsen. In 2021, more than one million people globally died due to bacterial infections resistant to antibiotics, and this number is expected to double by 2050. Given the serious implications, addressing such infections is crucial. Researchers are now exploring ways to reduce the rise of antibiotic-resistant infections in open bone fractures by using nanotechnology to enhance an ancient treatment.

The work by researchers at West Virginia University (WVU, Morgantown, WV, USA) focuses on developing a hybrid of two antimicrobial materials—silver and carbon nanotubes—on the nanometer scale to combat antibiotic-resistant infections in open fractures. Silver has long been used for its antimicrobial properties, while carbon nanotubes, commonly used in drug delivery and non-invasive monitoring, also exhibit antimicrobial effects. Nanotechnology enables the use of minuscule particles that can penetrate areas larger particles cannot. These particles can easily pass through cell membranes and kill bacteria. However, challenges arise as these particles may also affect human cells, potentially causing toxicity. One of the researchers' goals is to determine the appropriate formulation and particle size to ensure safety while maximizing effectiveness.

The team plans to test the hybrid silver nanoparticle-carbon nanotube combination using human cells in laboratory settings and in rats to evaluate its ability to combat various bacteria with minimal toxicity to both human and rat cells. They also aim to bioengineer the nanohybrids as coatings for orthopedic implants to test their antimicrobial properties. The researchers hope this study will extend beyond addressing antibiotic-resistant infections in bone fractures and demonstrate that nanohybrids can be applied to a wide range of medical devices, such as bone grafts, dental implants, catheters, bandages, and needles, to prevent infections during medical procedures.

Related Links:
West Virginia University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.